小分子 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "小分子" in Chinese language version.

refsWebsite

Global rank Chinese rank

2^nd place

23^rd place

4^th place

5^th place

3^rd place

8^th place

1^st place

books.google.com

Macielag MJ. Chemical properties of antibacterials and their uniqueness. Dougherty TJ, Pucci MJ (编). Antibiotic Discovery and Development. 2012: 801–2 [2020-01-16]. ISBN 978-1-4614-1400-1. （原始内容存档于2020-08-18）. The majority of [oral] drugs from the general reference set have molecular weights below 550. In contrast the molecular-weight distribution of oral antibacterial agents is bimodal: 340–450 Da but with another group in the 700–900 molecular weight range.
Samanen J. Chapter 5.2 How do SMDs differ from biomolecular drugs?. Ganellin CR, Jefferis R, Roberts SM (编). Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies Kindle. New York: Academic Press. 2013: 161–203 [2020-01-16]. ISBN 978-0-12-397176-0. doi:10.1016/B978-0-12-397176-0.00005-4. （原始内容存档于2020-09-02）. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally

Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Reviews Drug Discovery. April 2004, 3 (4): 301–17. PMID 15060526. doi:10.1038/nrd1343.
Samanen J. Chapter 5.2 How do SMDs differ from biomolecular drugs?. Ganellin CR, Jefferis R, Roberts SM (编). Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies Kindle. New York: Academic Press. 2013: 161–203 [2020-01-16]. ISBN 978-0-12-397176-0. doi:10.1016/B978-0-12-397176-0.00005-4. （原始内容存档于2020-09-02）. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45 (12): 2615–23. PMID 12036371. doi:10.1021/jm020017n.
Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 2004, 1 (4): 337–341. PMID 24981612. doi:10.1016/j.ddtec.2004.11.007.
Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery. 2007, 6 (11): 881–90. PMID 17971784. doi:10.1038/nrd2445.

Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Reviews Drug Discovery. April 2004, 3 (4): 301–17. PMID 15060526. doi:10.1038/nrd1343.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45 (12): 2615–23. PMID 12036371. doi:10.1021/jm020017n.
Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 2004, 1 (4): 337–341. PMID 24981612. doi:10.1016/j.ddtec.2004.11.007.
Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery. 2007, 6 (11): 881–90. PMID 17971784. doi:10.1038/nrd2445.

Macielag MJ. Chemical properties of antibacterials and their uniqueness. Dougherty TJ, Pucci MJ (编). Antibiotic Discovery and Development. 2012: 801–2 [2020-01-16]. ISBN 978-1-4614-1400-1. （原始内容存档于2020-08-18）. The majority of [oral] drugs from the general reference set have molecular weights below 550. In contrast the molecular-weight distribution of oral antibacterial agents is bimodal: 340–450 Da but with another group in the 700–900 molecular weight range.
Samanen J. Chapter 5.2 How do SMDs differ from biomolecular drugs?. Ganellin CR, Jefferis R, Roberts SM (编). Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies Kindle. New York: Academic Press. 2013: 161–203 [2020-01-16]. ISBN 978-0-12-397176-0. doi:10.1016/B978-0-12-397176-0.00005-4. （原始内容存档于2020-09-02）. Table 5.13: Route of Administration: Small Molecules: oral administration usually possible; Biomolecules: Usually administered parenterally